Adverum Biotechnologies Toekomstige groei

Future criteriumcontroles 2/6

De winst van Adverum Biotechnologies zal naar verwachting dalen met 14.2% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 41.3% per jaar. De winst per aandeel zal naar verwachting groeien met 6.7% per jaar.

Belangrijke informatie

-14.2%

Groei van de winst

6.7%

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	41.3%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	22 Nov 2024

Recente toekomstige groei-updates

Recent updates

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Nov 18

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Feb 24

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Sep 07

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Aug 11

Adverum gains 13% to reach three-month high after Truist upgrade

Jul 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

May 12

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Jul 17

Adverum Biotechnologies: An Uncertain Path Forward

May 05

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

May 03

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Apr 06

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Feb 13

Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy

Feb 02

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Jan 22

Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market

Jan 11

Adverum Biotechnologies announces new GMP gene therapy manufacturing facility

Jan 07

How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Dec 31

Winst- en omzetgroeiprognoses

NasdaqCM:ADVM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	20	-131	-133	N/A	5
12/31/2025	13	-119	-31	-119	8
12/31/2024	1	-101	-98	-91	8
9/30/2024	1	-94	-86	-86	N/A
6/30/2024	N/A	-100	-89	-88	N/A
3/31/2024	N/A	-113	-93	-92	N/A
12/31/2023	4	-117	-92	-91	N/A
9/30/2023	4	-126	-89	-88	N/A
6/30/2023	4	-133	-97	-96	N/A
3/31/2023	4	-146	-109	-102	N/A
12/31/2022	N/A	-155	-120	-108	N/A
9/30/2022	N/A	-156	-131	-115	N/A
6/30/2022	N/A	-154	-130	-109	N/A
3/31/2022	N/A	-155	-133	-114	N/A
12/31/2021	8	-146	-123	-108	N/A
9/30/2021	8	-149	-116	-104	N/A
6/30/2021	8	-138	-115	-105	N/A
3/31/2021	8	-123	-97	-88	N/A
12/31/2020	N/A	-118	-91	-79	N/A
9/30/2020	N/A	-99	-91	-72	N/A
6/30/2020	0	-87	-77	-55	N/A
3/31/2020	0	-73	-71	-50	N/A
12/31/2019	0	-64	-68	-49	N/A
9/30/2019	0	-61	-58	-47	N/A
6/30/2019	1	-66	-60	-54	N/A
3/31/2019	1	-70	-57	-54	N/A
12/31/2018	2	-73	-55	-54	N/A
9/30/2018	2	-72	-54	-53	N/A
6/30/2018	2	-65	N/A	-47	N/A
3/31/2018	2	-57	N/A	-47	N/A
12/31/2017	2	-56	N/A	-45	N/A
9/30/2017	2	-64	N/A	-42	N/A
6/30/2017	2	-64	N/A	-41	N/A
3/31/2017	2	-114	N/A	-38	N/A
12/31/2016	1	-114	N/A	-38	N/A
9/30/2016	2	-105	N/A	-39	N/A
6/30/2016	2	-105	N/A	-39	N/A
3/31/2016	2	-53	N/A	-40	N/A
12/31/2015	2	-47	N/A	-35	N/A
9/30/2015	2	-44	N/A	-31	N/A
6/30/2015	1	-38	N/A	-27	N/A
3/31/2015	1	-36	N/A	-12	N/A
12/31/2014	1	-29	N/A	-6	N/A
9/30/2014	0	-22	N/A	-1	N/A
6/30/2014	0	-14	N/A	3	N/A
3/31/2014	0	-7	N/A	-3	N/A
12/31/2013	0	-5	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ADVM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ADVM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ADVM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ADVM ( 41.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van ADVM ( 41.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ADVM naar verwachting over 3 jaar hoog zal zijn

Adverum Biotechnologies Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to US$3.67

Price target decreased to US$3.67

Price target increased to US$4.33

Price target increased to US$4.33

Price target increased to US$4.33

Price target decreased to US$3.57

Recent updates

Adverum Biotechnologies Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Price target decreased to US$3.67

Price target decreased to US$3.67

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Price target increased to US$4.33

Adverum gains 13% to reach three-month high after Truist upgrade

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

Price target increased to US$4.33

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold US$109k worth of stock

Price target increased to US$4.33

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Price target decreased to US$3.57

Consensus revenue estimates increase to US$6.00m

Consensus forecasts updated

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Adverum Biotechnologies: An Uncertain Path Forward

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

Price target decreased to US$17.11

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Independent Chairman recently bought US$99k worth of stock

New 90-day low: US$10.55

Analysts lower revenue estimates to US$230.0k

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

New 90-day high: US$14.36